Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

955
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
955
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

754
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
754

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.

The Journal of experimental medicine·2026
Same author

Early brain-penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1-related Aicardi-Goutières syndrome.

Clinical & translational immunology·2026
Same author

Nuclear STING compromises replication fidelity.

Nature reviews. Immunology·2026
Same author

Familial lupus associated with a <i>P2RY8</i> variant: Navigating the boundary between monogenic disease and genetic susceptibility to lupus.

Journal of human immunity·2026
Same author

A transcriptomic microglia taxonomy across mouse and human pathologies.

Nature immunology·2026
Same author

<i>TLR7</i> mutations leading to enhanced TLR7 signaling in humans.

Journal of human immunity·2026

Related Experiment Video

Updated: Jun 10, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.3K

CNS disease associated with enhanced type I interferon signalling.

Yanick J Crow1

  • 1Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.

The Lancet. Neurology
|October 18, 2024
PubMed
Summary

Type I interferons protect against neurotropic viruses but can harm the brain. Dysregulation of these interferons is linked to neurodegenerative diseases, suggesting new therapeutic targets.

More Related Videos

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

9.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

Related Experiment Videos

Last Updated: Jun 10, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.3K
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

9.2K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

Area of Science:

  • Neuroimmunology
  • Viral Pathogenesis
  • Neurodegenerative Diseases

Background:

  • Type I interferons are crucial for innate immunity against neurotropic viruses.
  • Antiviral type I interferons possess neurotoxic potential, with implications for brain health.
  • Inappropriate type I interferon signaling can be triggered by self-derived nucleic acids in the brain.

Purpose of the Study:

  • To explore the dual role of type I interferons in neuroprotection and neurotoxicity.
  • To investigate the link between dysregulated type I interferon signaling and neurodegenerative disorders.
  • To highlight recent advances in understanding and managing type I interferonopathies and neurodegenerative diseases.

Main Methods:

  • Review of current literature on type I interferon signaling in the central nervous system.
  • Analysis of pathogenetic mechanisms in type I interferonopathies and neurodegenerative conditions.
  • Synthesis of recent diagnostic and therapeutic developments.

Main Results:

  • Homeostatic dysregulation of type I interferons is implicated in rare inborn errors of immunity (type I interferonopathies).
  • Dysregulated type I interferon signaling is increasingly recognized in common neurodegenerative disorders like Parkinson's, Alzheimer's, and ALS.
  • New insights reveal the role of aberrant type I interferon signaling in disease pathogenesis.

Conclusions:

  • Type I interferons play a complex role in brain health, offering protection but also posing risks.
  • Targeting type I interferons and their signaling pathways presents a promising future therapeutic strategy for neurological disorders.
  • Understanding type I interferon dysregulation is key to developing novel treatments for neurodegenerative diseases.